
Novo Nordisk’s oral diabetes drug safe and effective
pharmafile | June 12, 2019 | News story | Research and Development | GLP-1, Novo Nordisk, diabetes, pharma, samgalutide
Novo Nordisk’s oral diabetes drug semaglutide is safe for those at high risk of cardiovascular complications, according to the results of a Phase 3a trial.
The human glucagon-like peptide-1 (GLP-1) drug semgalutide is currently available as a once weekly injection for patients with type 2 diabetes.
The injectable version has been shown to reduce the risk of cardiovascular events, even among those at high risk.
The new Phase 3a trial found that the oral version of the drug was safe and superior to MSD’s sitagliptin in helping patients achieve their HbA1c targets.
The oral version of semgalutide has a safety profile consistent with the GPL-1 class of drugs as a whole.
“This is the first orally-available GLP-1 (glucagon-like peptide-1) receptor agonist and that’s a pretty big deal,” said Dr Mansoor Husain, director of the Toronto General Hospital Research Institute who led the study. “Just being able to take a pill every day makes it much more accessible.”
The results of the trial were published in the journal The Lancet Diabetes & Endocrinology.
Louis Goss
Related Content

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …

BioMed X and Novo Nordisk partner on oral peptide drug delivery innovation
BioMed X has announced a new collaboration with Novo Nordisk to improve oral delivery of …






